Advances in molecular biology have provided the basis for development of new therapeutic approaches to psoriasis. New, more effective therapies target specific molecules in the inflammatory cascade involved in the pathogenesis of psoriasis.The biologic era of psoriasis therapy began with inhibitors of T-cell activation, tumor necrosis factor-α, and interleukin (IL)-12/23. Continued investigation has led to therapies and therapeutic candidates that target IL-17, IL-23, phosphodiesterase-4, and isomers of Janus kinase.
Keywords: JAK interlukin-17 inhibitors; Janus kinase inhibitors; apremilast; brodalumab; inflammation; interleukin-12/23; ixekizumab; monoclonal antibody; phosphodiesterase-4; psoriasis; secukinumab; tofacitinib; tumor necrosis factors.
2014 by Frontline Medical Communications Inc.